Especially Ibrutinib, an inhibitor for Bruton's tyrosine kinase (BTK), has been approved and is widely used as a successful therapy against CLL (Burger & Chiorazzi, 2013; Hallek & Furstenau, 2019). Here, BTK is linked to B-cell chronic lymphocytic leukemia.